Official Title
Neurologic Manifestations of COVID 19 in Children
Brief Summary

This is a multicenter, multinational observational cohort study to document neurologic manifestations of COVID 19 among pediatric patients requiring hospital admission for confirmed or suspected COVID 19 (Coronavirus 19 disease, caused by infection with the SARS-CoV-2 (acute respiratory syndrome 2 ) virus. SARS-CoV2 shares significant structural and biological similarities with SARS-CoV including using the ACE-2 receptor as a docking site, a property that confers neurotropism. This study is sponsored and led by members of the Pediatric Neurocritical Care Research Group (PNCRG).

Detailed Description

Early reports of COVID-19 indicate that adults experience a variety of neurological symptoms and diagnoses in approximately 36% of patients, including headaches, seizures, coma, encephalitis, and cerebrovascular events including ischemic stroke, intracranial hemorrhage, and cerebral venous sinus thromboses. In children, recent evidence highlights acute and long-term neurological manifestations due to other viral illnesses including Guillain Barre syndrome and neonatal microcephaly with Zika virus, encephalitis with H1N1 influenza, and acute flaccid paralysis with enterovirus-68. However, COVID-19 reports in children published thus far lack detailed information on the frequency and outcomes of neurological findings.

COVID-19 cases are rapidly rising internationally, with experts forecasting subsequent global surges and continued activity. Thus, it is imperative to accurately document prevalence and outcomes of the neurological aspects of COVID-19 specifically in children. Such data will serve to alert clinicians and families about the possibility that children may present with neurologic rather than "classic" symptoms of COVID-19 who nevertheless would warrant testing, and that neurologic events can occur subsequent to the diagnosis that may impact long-term outcomes (e.g., cognitive, emotional, physical health). The investigators anticipate that improved knowledge about neurologic manifestations in children will bolster personalized treatment and rehabilitation strategies to optimize child outcomes and inform future interventional studies.

Neurologic Manifestations

Other: Observational study only
No Intervention
Children <18

Eligibility Criteria

Inclusion Criteria:

- Infants, children, and young adults age < 18 years

- Admitted to the hospital with confirmed or presumed COVID-19 infection (includes admissions to emergency, ward, intensive care etc.)

Exclusion Criteria:

- none

Eligibility Gender
Eligibility Age
Maximum: 17 Years
United States

UPMC Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15224


Investigator: Ericka L Fink


Ericka L Fink, MD

David Maloney, BS

Ericka L Fink, MD
Principal Investigator
University of Pittsburgh

University of Pittsburgh
University of Utah
Johns Hopkins University
NCT Number
neurocritical care
neurologic manifestations
MeSH Terms
Neurologic Manifestations